Home » Topics » BioWorld Science, Infection

BioWorld Science, Infection
RSS

Enrollment ongoing in phase II study of IC-14 chimeric antibody in patients with COVID-19

April 8, 2021

Shionogi and Hsiri Therapeutics patent compounds for mycobacterial infections

April 8, 2021

AzurRx starts phase II RESERVOIR study in patients with COVID-19 GI infection

April 7, 2021

Study shows neurological or psychiatric diagnoses for 1 in 3 COVID-19 survivors

April 7, 2021

MfpA protein acts a T-segment mimic to protect DNA gyrase from fluoroquinolones

April 7, 2021

Pfizer's oral SARS-CoV-2 main protease inhibitor PF-07321332 enters phase I

April 7, 2021

First patient dosed in a phase II study of ensovibep for the treatment of COVID-19

April 7, 2021

Zydus reports positive phase III data for PegiHep in patients with COVID-19

April 7, 2021

New nitazoxanide derivatives synthesized at Beijing Junke Huayuan Med Tech

April 6, 2021

Positive phase I/II data for VLA-2001 COVID-19 vaccine candidate

April 6, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
Deep brain stimulation from the shallows: tomorrow’s BCI technology?
BioWorld
Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Deerfield-backed Boulevard, Metis pen $1.6B trispecific TCE deal
BioWorld
A U.S. biotechnology company founded by Deerfield Management Company L.P. licensed exclusive rights to Metis Techbio Co. Ltd.’s preclinical trispecific T-cell...